Gilead Sciences reported $2.03 in EPS Earnings Per Share for its fiscal quarter ending in March of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q1 Mar/2026 2.03 1.9 1.81 May/07
FY2025Q4 Dec/2025 1.86 1.89 1.90 Feb/10
FY2025Q3 Sep/2025 2.47 2.16 2.02 Oct/30
FY2025Q2 Jun/2025 2.01 1.94 2.01 Aug/07
FY2025Q1 Mar/2025 1.81 1.76 3.34 Apr/24




Eps Change Date
AbbVie USD 2.65 0.06 Mar/2026
Agios Pharmaceuticals USD -1.69 0.17 Mar/2026
ALKERMES USD -0.4 0.69 Mar/2026
Alnylam Pharmaceuticals USD 1.99 0.74 Mar/2026
Amgen USD 5.15 0.14 Mar/2026
Biogen USD 3.57 1.58 Mar/2026
BioMarin Pharmaceutical USD 0.76 0.3 Mar/2026
Bristol-Myers Squibb USD 1.58 0.32 Mar/2026
Coherus Biosciences USD -0.43 0.06 Dec/2025
Eli Lilly USD 8.55 1.01 Mar/2026
Gilead Sciences USD 2.03 0.17 Mar/2026
GlaxoSmithKline GBP 0.43 0.17 Mar/2026
Glaxosmithkline GBP 0.62 0.41 Mar/2026
Incyte USD 1.81 0.01 Mar/2026
J&J USD 2.7 0.24 Mar/2026
Merck USD -1.28 3.32 Mar/2026
Moderna USD -3.4 1.29 Mar/2026
Neurocrine Biosciences USD 1.94 0.06 Mar/2026
Novartis USD 1.99 0.04 Mar/2026
Pfizer USD 0.75 0.09 Mar/2026
PTC Therapeutics USD -0.03 1.64 Mar/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 9.47 1.97 Mar/2026
Sangamo BioSciences USD -0.18 0.1 Jun/2024
Sanofi EUR 1.88 0.35 Mar/2026
Sarepta Therapeutics USD 3.16 6.74 Mar/2026
United Therapeutics USD 5.82 1.88 Mar/2026
Vertex Pharmaceuticals USD 4.47 0.56 Mar/2026